Integra Lifesciences Holdings Corp at JPMorgan Healthcare Conference Transcript
Hello, everyone. I'm Robbie Marcus, the medical device analyst here at JPMorgan. I'm very happy to introduce our next speaker, Pete Arduini, the CEO of Integra LifeSciences. Pete?
Thanks, Robbie. Good afternoon, everyone. I hope everyone's doing well. I'll start off with giving a little bit of an overview. We have some safe harbor statements here as well as I'll be using some non-GAAP financial metrics to talk a little bit about our numbers.
Integra by the numbers, for those that may not know the company that well, we are a company that, based on our 2019 numbers, roughly about $1.5 billion of revenue, of which 65% is in our Codman Specialty Surgical business, which is a combination of specialty instrumentation as well as a broad array of products that a neurosurgeon would use on a regular basis. And then 35% of the business is our Orthopedics and Tissue Technologies business. The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
